200 related articles for article (PubMed ID: 24967520)
1. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
Kaisaeng N; Harpe SE; Carroll NV
J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
[TBL] [Abstract][Full Text] [Related]
2. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
3. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
4. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
5. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
6. In-gap discounts in Medicare Part D and specialty drug use.
Jung J; Xu WY; Cheong C
Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
[TBL] [Abstract][Full Text] [Related]
7. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
8. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
9. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
10. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
Shen C; Zhao B; Liu L; Shih YT
J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
[TBL] [Abstract][Full Text] [Related]
11. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
12. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
13. Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke.
Salam T; Desai U; Lefebvre P; Jian-Yu E; Greatsinger A; Zacharia N; Laliberté F; Bookhart B; Kharat A
Adv Ther; 2023 Oct; 40(10):4523-4544. PubMed ID: 37568060
[TBL] [Abstract][Full Text] [Related]
14. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
[TBL] [Abstract][Full Text] [Related]
16. Access to oral osteoporosis drugs among female Medicare Part D beneficiaries.
Lin CW; Karaca-Mandic P; McCullough JS; Weaver L
Womens Health Issues; 2014; 24(4):e435-45. PubMed ID: 24837398
[TBL] [Abstract][Full Text] [Related]
17. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer.
Davidoff AJ; Erten M; Shaffer T; Shoemaker JS; Zuckerman IH; Pandya N; Tai MH; Ke X; Stuart B
Cancer; 2013 Mar; 119(6):1257-65. PubMed ID: 23225522
[TBL] [Abstract][Full Text] [Related]
18. Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure.
McGee BT; Phillips V; Higgins MK; Butler J
J Manag Care Spec Pharm; 2019 Jun; 25(6):705-713. PubMed ID: 31134861
[TBL] [Abstract][Full Text] [Related]
19. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Neuner JM; Kamaraju S; Charlson JA; Wozniak EM; Smith EC; Biggers A; Smallwood AJ; Laud PW; Pezzin LE
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971298
[TBL] [Abstract][Full Text] [Related]
20. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
